Aerocrine strengthens its patent portfolio

Aerocrine strengthens its patent portfolio

SOLNA - 9 January 2008 - Aerocrine AB (OMX Nordic Exchange: AERO) announces that
the company has strengthened its patent portfolio by both acquiring a
strategically important patent and patenting its own discoveries.

Aerocrine has acquired a patent that describes how to electronically control the
flow of exhaled air when measuring nitric oxide. Repeated exhalation with
different airflows allows airway inflammation to be localized peripherally or
centrally. This could be highly significant both for diagnosis and when choosing
medication for patients with asthma-like symptoms, and in cases of suspected
COPD. The discovery comes from a Finnish research group led by Professor Eeva
Moilanen and Dr Lauri Lehtimäki Medical School, University of Tampere.
Electronically controlling the flow of exhaled air enables quick and controlled
measurements. Aerocrine uses this new technology in its latest product, NIOX®
Flex. 

Over the past year, the company also gained approval in the US for the first
patent in a completely new patent family. This patent involves a way of
measuring whether patients who have undergone polyp surgery have improved nasal
flow through. 

An early focus on patents from Aerocrine's founders provides the foundation for
the company's broad patent portfolio. The company's patents are distributed over
three business areas and 13 separate patent families. Continuous technological
development with a clear patent focus is a critical part of the company's
long-term strategy.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
08:00 AM on January 9, 2008.

About Aerocrine
Aerocrine AB is a clinically based medical technology corporation dedicated to
improved asthma management and care. Aerocrine was listed on the Stockholm Stock
Exchange on 15 June, 2007. The company is marketing NIOX® Flex on a worldwide
basis and is also marketing NIOX MINO®, representing a new generation of
hand-held devices, in Europe. Both products are tailored for rapid, non-invasive
control of the inflammatory status in the airways and may play a critical role
for optimized asthma care and disease control. Aerocrine is located in Sweden
with wholly owned subsidiaries in the US, UK and Germany.